Company: MIRM
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001759425-25-000054
Chunk: 413

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 8
Chunk 413
---
$372,380 $236,979 License and other revenue— 75 — 495 Total revenue133,010 90,377 372,380 237,474 Less:Cost of sales (excluding intangible amortization and other non-cash expenses)19,643 13,118 54,294 35,614 General and administrative expenses (excluding stock-based compensation)13,189 10,796 37,960 32,818 Commercialization and Medical Affairs expenses (excluding stock-based compensation)36,599 31,731 111,971 88,995 Research and development expenses (excluding stock-based compensation)37,284 28,139 116,542 85,626 Stock-based compensation17,798 11,589 51,500 34,556 Intangible amortization and other non-cash expenses5,894 7,688 17,682 23,249 Income (loss) from operations$2,603 $(12,684)$(17,569)$(63,384)

13. Commitments and Contingencies

Certain of the Company’s contractual arrangements with contract manufacturing organizations require binding forecasts or commitments to purchase minimum amounts for the manufacture of drug product supply, which may be material to the Company's unaudited condensed consolidated financial statements.The Company is subject to potential liabilities under government regulations and various claims and legal actions that are pending or may be asserted from time-to-time. These matters arise in the ordinary course and conduct of the Company’s business and may include, for example, commercial, intellectual property, and employment matters. The 

21

Company intends to defend itself vigorously in such matters and when warranted, take legal action against others. Furthermore, the Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its unaudited condensed consolidated financial statements.An estimated loss contingency is accrued in the Company’s unaudited condensed consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company does not accrue amounts for liabilities that it does not believe are probable. Litigation is inherently unpredictable, and unfavorable resolutions could occur. As a result, assessing contingencies is highly subjective and requires judgment about future events. During the periods presented, the Company has not recorded any accrual for loss contingencies associated with government regulations, claims or legal actions, determined that an unfavorable outcome is probable or reasonably possible